BR0212824A - Pharmaceutical Composition - Google Patents

Pharmaceutical Composition

Info

Publication number
BR0212824A
BR0212824A BR0212824-1A BR0212824A BR0212824A BR 0212824 A BR0212824 A BR 0212824A BR 0212824 A BR0212824 A BR 0212824A BR 0212824 A BR0212824 A BR 0212824A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
mammal
salts
compound selected
Prior art date
Application number
BR0212824-1A
Other languages
Portuguese (pt)
Inventor
Stephen P Arneric
Per-Olof Andersson
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/965,556 external-priority patent/US20030060513A1/en
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of BR0212824A publication Critical patent/BR0212824A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA". A presente invenção refere-se ao campo da urologia. A invenção proporciona uma nova composição farmacêutica, a qual compreende uma combinação farmaceuticamente eficaz de (I) um primeiro composto selecionado do grupo que consiste de antagonistas de receptores muscarínicos, inibidores de 5<244>-reductase e antagonistas de receptores <244>-adrenérgicos, e precursores e sais farmaceuticamente aceitáveis dos mesmos, e (ii) um segundo composto selecionado do grupo que consiste de agonistas e antagonistas de receptor de 5-HT~ 1a~, e precursores e sais farmaceuticamente aceitáveis dos mesmos, e opcionalmente um veículo ou diluente farmaceuticamente aceitável para essa composição. é também proporcionado um método de tratamento terapêutico de distúrbio urinário em um mamífero, incluindo o homem, método este que compreende administrar nesse mamífero, incluindo o homem, com necessidade desse tratamento, uma quantidade terapeuticamente eficaz de uma composição de acordo com a invenção."PHARMACEUTICAL COMPOSITION". The present invention relates to the field of urology. The invention provides a novel pharmaceutical composition which comprises a pharmaceutically effective combination of (I) a first compound selected from the group consisting of muscarinic receptor antagonists, 5β-reductase inhibitors and β-adrenergic receptor antagonists. , and pharmaceutically acceptable precursors and salts thereof, and (ii) a second compound selected from the group consisting of 5-HT-1α receptor agonists and antagonists, and pharmaceutically acceptable precursors and salts thereof, and optionally a carrier or pharmaceutically acceptable diluent for such a composition. Also provided is a method of therapeutically treating urinary disorder in a mammal, including man, which method comprises administering to that mammal, including man, in need of such treatment, a therapeutically effective amount of a composition according to the invention.

BR0212824-1A 2001-09-27 2002-09-26 Pharmaceutical Composition BR0212824A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/965,556 US20030060513A1 (en) 2001-09-27 2001-09-27 Pharmaceutical composition
SE0103858A SE0103858D0 (en) 2001-09-27 2001-11-20 Pharmaceutical composition
PCT/SE2002/001748 WO2003026564A2 (en) 2001-09-27 2002-09-26 Pharmaceutical compositions for the treatment of urinary disorders

Publications (1)

Publication Number Publication Date
BR0212824A true BR0212824A (en) 2004-10-13

Family

ID=26655594

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212824-1A BR0212824A (en) 2001-09-27 2002-09-26 Pharmaceutical Composition

Country Status (9)

Country Link
EP (1) EP1438035A2 (en)
JP (1) JP2005503424A (en)
KR (1) KR20040039436A (en)
CN (1) CN1558756A (en)
BR (1) BR0212824A (en)
CA (1) CA2461731A1 (en)
IL (1) IL160852A0 (en)
MX (1) MXPA04002496A (en)
WO (1) WO2003026564A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (en) 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
FR2843303B1 (en) * 2002-08-07 2006-01-21 R & D Pharma NOVEL PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE
DE10315917A1 (en) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Highly pure bases of 3,3-diphenylpropylamine monoesters
CN100382794C (en) * 2004-08-30 2008-04-23 鲁南制药集团股份有限公司 Dispersed tablet of tartaric acid tolterodine tartrate
WO2009151613A1 (en) * 2008-06-13 2009-12-17 Concert Pharmaceuticals, Inc. Oxybutynin derivatives
US20110262566A1 (en) * 2008-11-07 2011-10-27 Dainippon Sumitomo Pharma Co., Ltd. Novel useful therapeutic agent for lower urinary tract symptom
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
AU2020257625A1 (en) 2019-04-17 2021-11-04 Compass Pathfinder Limited Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9417135D0 (en) * 1994-08-23 1994-10-12 Medinnova S F Method
IT1282705B1 (en) * 1996-02-28 1998-03-31 Recordati Chem Pharm USE OF 5-HT | A SEROTONINERGIC RECEPTOR ANTAGONISTS FOR THE TREATMENT OF URINARY INCONTINENCE
PE92198A1 (en) * 1996-08-01 1999-01-09 Banyu Pharma Co Ltd DERIVATIVES OF FLUORINE-CONTAINED 1,4-PIPERIDINE
EP1032400A4 (en) * 1997-10-28 2006-04-12 Merck & Co Inc Prevention of precipitated acute urinary retention
AU7703700A (en) * 1999-09-22 2001-04-24 Merck & Co., Inc. Treatment of lower urinary tract symptoms and pharmaceutical compositions for use therein
IT1314192B1 (en) * 1999-10-18 2002-12-06 Recordati Chem Pharm BENZOPYRANIC DERIVATIVES

Also Published As

Publication number Publication date
WO2003026564A3 (en) 2003-12-11
WO2003026564A9 (en) 2004-06-17
WO2003026564A2 (en) 2003-04-03
CA2461731A1 (en) 2003-04-03
JP2005503424A (en) 2005-02-03
CN1558756A (en) 2004-12-29
MXPA04002496A (en) 2004-05-31
EP1438035A2 (en) 2004-07-21
IL160852A0 (en) 2004-08-31
KR20040039436A (en) 2004-05-10

Similar Documents

Publication Publication Date Title
BR9813973A (en) Compound, process for preparing it, use of it, pharmaceutical composition, and process for the treatment of a patient suffering from a condition.
BRPI0409211A (en) compound, pharmaceutical composition, methods for activating 5-ht1f receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal, and, use of a compound
UA101601C2 (en) Inhibitors of fatty acid amide hydrolase
PT687251E (en) 1,3-DIHYDRO-INDOL-2-ONA DERIVATIVES SUBSTITUTED AT POSITION 3 BY A NITROGEN GROUP AS VASOPRESSIN AND / OR OCITOCIN AGONISTS OR ANTAGONISTS
BR0213612A (en) Compound, pharmaceutical composition, use of compound and method for treating disease or condition
BR9914164A (en) Compound, method for treating, inhibiting the growth of, or eradicating a neoplasm, and polycystic kidney disease, in a mammal in need thereof, pharmaceutical composition, and, process for preparing a compound
BR0016385A (en) Compounds or combinations thereof which have seratonin reuptake inhibitory activity and a 5-ht2c antagonist, inverse agonist or partial agonist; use thereof; pharmaceutical composition and method
ATE360630T1 (en) AZABICYCLIC HETEROCYCLES AS MODULATORS OF THE CANNABINOID RECEPTOR
DE69006684D1 (en) Use of a composition for the manufacture of a medicament for the treatment of the symptoms of abstinence.
BR0014384A (en) Compounds for the treatment of ischemia
BR9914901A (en) 5ht1 receptor agonists and metoclopramide for the treatment of migraine
BR0111377A (en) Thiophene derivatives useful as anticancer agents
BR0017338A (en) Compound, process for preparing a compound, pharmaceutical composition, and methods for treating a patient, for inhibiting c5a promoted cell chemotaxis, for localizing c5a receptors in a tissue, and for reducing the severity or frequency of one or more inflammatory transplant sequelae organ
BR9806060A (en) Compound, pharmaceutical composition and processes to treat a patient suffering from a sick condition, to inhibit factor xa, and to inhibit thrombin formation.
BR0212824A (en) Pharmaceutical Composition
BRPI0406883A (en) Compound, pharmaceutical composition, method of treating a disorder, and use of a compound
BR0213139A (en) Compound, method of treating or preventing disease and preparing a compound, use of a compound and pharmaceutical composition
CA2376916A1 (en) Anaesthetic formulation comprising an nmda-antagonist and an alpha-2 adrenergic agonist
BR0212787A (en) Pharmaceutically acceptable compound or salt thereof, methods of treating or preventing disease and preparing a compound, use of a compound or salt, and pharmaceutical composition
BRPI0507657A (en) compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, method for treating a disorder, and use of a compound or a pharmaceutically acceptable salt thereof
BR0215430A (en) Compound and its uses, composition, method of treatment, method of increasing cholinergic receptor activity, method of treatment and prevention or reduction of symptoms associated with dysfunction in mammals
BR9908470A (en) Compound, pharmaceutical composition, and process to treat conditions mediated by avb3 inegrin in a mammal in need of such treatment
BR0200246A (en) Combination treatment for depression
BR9908125A (en) Compound, dimeric compound, pharmaceutical composition, use of the compound, process comprising inhibiting cancer cells, and, therapeutic process
BR0311136A (en) compound or a pharmaceutically acceptable salt, enanciomer, diastereomer or ester in vivo or mixture thereof, composition, and method for inhibiting the lethal factor (lf) activity released from bacteria in a mammal

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A E 7A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2034 DE 29/12/2009.